Program
Memantine
Also written as “Memantine Hydrochloride (HCl)”, “memantine” and “memantine HCl”.
Its studies are mostly in Alzheimer Disease · Autistic Disorder · Autism Spectrum Disorder · Glaucoma, Open-Angle · Cancer Pain, led by 7 companies.
Drug pageMemantine: every studyMany companies study it; this page follows only the 27 they lead. All 198 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 130 open or running | phase 4since Jun 6, 2006 | Dec 1, 2004 | none ahead |
| H. Lundbeckits history only | 60 open or running | phase 4since Mar 3, 2009 | Mar 3, 2009 | none ahead |
| Merz Pharmaits history only | 40 open or running | phase 4since Mar 27, 2008 | Feb 14, 2008 | none ahead |
| Carnot Laboratoriesits history only | 10 open or running | phase 4since Feb 11, 2026 | Feb 11, 2026 | none ahead |
| Gedeon Richter Plc.its history only | 10 open or running | phase 1since Nov 15, 2013 | Nov 15, 2013 | none ahead |
| Geropharmits history only | 10 open or running | phase 1since Apr 18, 2017 | Apr 18, 2017 | none ahead |
| Mendel AIits history only | 10 open or running | phase 3since Jan 30, 2021 | Jan 30, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AbbVie only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 1, 2004First study: phase 2 study in SchizophreniaFirst studyNCT00097942 · 138 enrolled · United States
- Dec 1, 2004Phase 3 study in Alzheimer DiseaseNCT00097916 · 34 enrolled · United States
- Mar 24, 2005Phase 2 study in Bipolar DisorderNCT00106405 · 35 enrolled · United States
- Aug 31, 2005Phase 3 study in Glaucoma, Open-AngleNCT00141882 · 1,119 enrolled
- Sep 9, 2005Phase 3 study in Glaucoma, Open-AngleNCT00168350 · 1,179 enrolled
- May 3, 2006Phase 3 study in Alzheimer DiseaseNCT00322153 · 677 enrolled · United States, Argentina, Chile and more
- Jun 6, 2006Phase 4 study in Alzheimer DiseaseNCT00334906 · 75 enrolled · United States
- May 2, 2007Phase 4 study in Alzheimer DiseaseNCT00469456 · 265 enrolled · Australia, New Zealand, South Africa
- Mar 30, 2009Phase 2 study in Autistic DisorderNCT00872898 · 124 enrolled · United States
- May 3, 20123 phase 2 studiesNCT01592786, NCT01592773, NCT01592747
- Nov 26, 2013Phase 2 study in Autistic DisorderNCT01999894 · 102 enrolled · United States
TargetBeta
“Glutamate [NMDA] receptor negative allosteric modulator”ChEMBL 37, by rule
Other programs on the same 7 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esketaminerule | Johnson & Johnson | phase 4 | 51 |
Studies
All 13 AbbVie leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01999894Autistic Disorder · United States | 2 | Completed | Feb 2013 | 102 |
| NCT01592786Autism Spectrum Disorder · United States, Australia, Belgium and more | 2 | Completed | Jul 2013 | 906 |
| NCT01592773Autism Spectrum Disorder · United States, Belgium, Canada and more | 2 | Terminated | Jan 2014 | 747 |
| NCT01592747Autistic Disorder · United States, Belgium, Colombia and more | 2 | Completed | Sep 2013 | 479 |
| NCT00872898Autistic Disorder · United States | 2 | Completed | Aug 2012 | 124 |
| NCT00469456Alzheimer Disease · Australia, New Zealand, South Africa | 4 | Completed | Nov 2008 | 265 |
| NCT00334906Alzheimer Disease · United States | 4 | Completed | Nov 2007 | 75 |
| NCT00322153Alzheimer Disease · United States, Argentina, Chile and more | 3 | Completed | Oct 2007 | 677 |
| NCT00168350Glaucoma, Open-Angle | 3 | Completed | Sep 2006 | 1,179 |
| NCT00141882Glaucoma, Open-Angle | 3 | Completed | Jan 2006 | 1,119 |
| NCT00106405Bipolar Disorder · United States | 2 | Completed | Nov 2005 | 35 |
| NCT00097942Schizophrenia · United States | 2 | Completed | Sep 2005 | 138 |
| NCT00097916Alzheimer Disease · United States | 3 | Completed | Apr 2006 | 34 |
How it is read
Names in the registry
- “Memantine”, 11 entries
- “Memantine Hydrochloride (HCl)”, 4 entries
- “memantine”, 3 entries
- “memantine HCl”, 3 entries
- “Memantine HCl”, 2 entries
Conditions, from the studies’ own filings
- Alzheimer Disease, 14 studies
- Autistic Disorder, 3 studies
- Autism Spectrum Disorder, 2 studies
- Glaucoma, Open-Angle, 2 studies
- Cancer Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.